Synopsis
Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Dexambutol
2. Emb Fatol
3. Emb Hefa
4. Emb-fatol
5. Emb-hefa
6. Etambutol Llorente
7. Ethambutol
8. Etibi
9. Hydrochloride, Ethambutol
10. Llorente, Etambutol
11. Miambutol
12. Myambutol
1. Ethambutol Dihydrochloride
2. Ethambutol Hcl
3. 1070-11-7
4. Myambutol
5. Dadibutol
6. Dexambutol
7. Etibi
8. Ethambutol (dihydrochloride)
9. Servambutol
10. Etapiam
11. Mycobutol
12. Tambutol
13. Ebutol
14. Cl 40881
15. Tibutol
16. (2s,2's)-2,2'-(ethane-1,2-diylbis(azanediyl))bis(butan-1-ol) Dihydrochloride
17. Jng307dj5x
18. Qe4vw5fo07
19. Ethambutol Dihydrochloride, Dl-
20. (+)-2,2'-(ethylenediimino)-di-1-butanol Dihydrochloride
21. Nsc-757022
22. Cl-40881
23. 22196-75-4
24. Dsstox_cid_25345
25. Dsstox_rid_80813
26. Dsstox_gsid_45345
27. Ethambutol 2hcl
28. Emb Dihydrochloride
29. Chebi:4878
30. (2s)-2-[2-[[(1s)-1-(hydroxymethyl)propyl]amino]ethylamino]butan-1-ol Dihydrochloride
31. (2s)-2-[2-[[(2s)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;dihydrochloride
32. Ccris 6606
33. Ncgc00178864-03
34. Einecs 213-970-7
35. Unii-jng307dj5x
36. Unii-qe4vw5fo07
37. (+-)-ethambutol Dihydrochloride
38. Myambutol (tn)
39. Ethambutol Hydrochloride [usan:usp:jan]
40. Ethambutoli Hydrochloridum
41. Emb
42. Ncgc00016560-01
43. Cas-1070-11-7
44. (2s)-2-[(2-{[(2s)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol Dihydrochloride
45. Schembl650049
46. Spectrum1500288
47. Chembl3140361
48. Dtxsid4045345
49. Hy-b0535a
50. (+-)-2,2'-(ethylenediimino)-di-1-butanol Dihydrochloride
51. Hms1920m18
52. Kuc109574c
53. (s-(r*,r*))-2,2'-(ethylenediimino)dibutan-1-ol Dihydrochloride
54. Ksc-27-052b
55. Tox21_110494
56. 1-butanol, 2,2'-(ethylenediimino)di-, Dihydrochloride, (+)-
57. Ccg-40232
58. Mfcd21364080
59. S4004
60. Ethambutol Hydrochloride (jp17/usp)
61. Ethambutol Hydrochloride [jan]
62. 1-butanol, (1,2-ethanediyldiimino)bis-, Dihydrochloride, (r*,r*)-(+-)-
63. Akos024258527
64. Tox21_110494_1
65. Cl40881
66. Ethambutol Dihydrochloride [mi]
67. Ethambutol Hydrochloride [usan]
68. Nsc 757022
69. 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-, Dihydrochloride, (r-(r*,r*))-
70. 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-, Dihydrochloride, (s-(r*,r*))-
71. Ethambutol Hydrochloride [mart.]
72. Ethambutol Hydrochloride [vandf]
73. Ethambutol Hydrochloride [usp-rs]
74. Ethambutol Hydrochloride [who-ip]
75. Ethambutol Dihydrochloride [who-dd]
76. Ethambutol Dihydrochloride, Antimycobacterial
77. E1011
78. Sw219109-1
79. Ethambutol Hydrochloride [ep Impurity]
80. Ethambutol Hydrochloride [orange Book]
81. D00878
82. Ethambutol Hydrochloride [ep Monograph]
83. Ethambutol Hydrochloride [usp Monograph]
84. Ethambutoli Hydrochloridum [who-ip Latin]
85. A895715
86. Q27106530
87. Z1558572530
88. 2,2'-(1,2-ethanediyldiimino)bis-1-butanol Dihydrochloride
89. 2,2'-[ethane-1,2-diyldi(imino)]dibutan-1-ol Dihydrochloride
90. (s,s)-2,2'-(1,2-ethanediyldiimino)bis-1-butanol Dihydrochloride
91. (s,s)-n,n'-bis(1-hydroxy-2-butyl)ethylenediamine Dihydrochloride
92. 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-, Dihydrochloride, (r*,r*)-
93. 1-butanol, 2,2'-(ethylenediimino)di-, Dihydrochloride, (+-)-
94. Ethambutol Hydrochloride, European Pharmacopoeia (ep) Reference Standard
95. 1-butanol, 2,2'(1,2-ethanediyldiimino)bis-, Dihydrochloride, (-(r*,r*))
96. 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-, Dihydrochloride, (2r,2'r)-rel-
97. 1-butanol, 2,2'-(1,2-ethanediyldiimino)bis-, Hydrochloride (1:2), (2s,2's)-
98. Ethambutol For System Suitability, European Pharmacopoeia (ep) Reference Standard
99. Ethambutol Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
100. Ethambutol Hydrochloride, United States Pharmacopeia (usp) Reference Standard
101. 29326-86-1
Molecular Weight | 277.23 g/mol |
---|---|
Molecular Formula | C10H26Cl2N2O2 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 9 |
Exact Mass | 276.1371335 g/mol |
Monoisotopic Mass | 276.1371335 g/mol |
Topological Polar Surface Area | 64.5 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 109 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Ethambutol hydrochloride |
Active Ingredient | Ethambutol hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 400mg |
Market Status | Prescription |
Company | Lupin; Barr |
2 of 2 | |
---|---|
Drug Name | Ethambutol hydrochloride |
Active Ingredient | Ethambutol hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 400mg |
Market Status | Prescription |
Company | Lupin; Barr |
Antitubercular Agents
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6382
Submission : 1986-05-27
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-01-12
Pay. Date : 2015-01-15
DMF Number : 11171
Submission : 1994-10-31
Status : Active
Type : II
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074Amended
Address of the Firm :
NDC Package Code : 65691-0014
Start Marketing Date : 1994-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20404
Submission : 2007-03-30
Status : Active
Type : II
Certificate Number : R1-CEP 2000-019 - Rev 06
Issue Date : 2021-03-18
Type : Chemical
Substance Number : 553
Status : Valid
Registration Number : 225MF10019
Registrant's Address : Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai 400055, India
Initial Date of Registration : 2013-02-05
Latest Date of Registration :
Date of Issue : 2022-09-30
Valid Till : 2025-09-10
Written Confirmation Number : WC-0201
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16466
Submission : 2003-03-13
Status : Inactive
Type : II
Certificate Number : CEP 2016-060 - Rev 01
Issue Date : 2025-04-08
Type : Chemical
Substance Number : 553
Status : Valid
Date of Issue : 2022-08-11
Valid Till : 2025-08-15
Written Confirmation Number : WC-0225
Address of the Firm :
Registration Number : 221MF10232
Registrant's Address : 11/12, Udyog Nagar, S. V. Road, Goregaon-West, Mumbai-400104, India
Initial Date of Registration : 2009-10-26
Latest Date of Registration :
Certificate Number : CEP 2023-224 - Rev 00
Issue Date : 2023-09-07
Type : Chemical
Substance Number : 553
Status : Valid
Date of Issue : 2022-08-11
Valid Till : 2025-08-15
Written Confirmation Number : WC-0225
Address of the Firm :
Registration Number : 218MF10556
Registrant's Address : 24-8 Tamura 9-chome, Hiratsuka City, Kanagawa Prefecture
Initial Date of Registration : 2006-06-02
Latest Date of Registration :
Date of Issue : 2022-03-06
Valid Till : 2025-07-31
Written Confirmation Number : WC-0048n
Address of the Firm :
Certificate Number : R1-CEP 2000-019 - Rev 06
Status : Valid
Issue Date : 2021-03-18
Type : Chemical
Substance Number : 553
Certificate Number : CEP 2016-060 - Rev 01
Status : Valid
Issue Date : 2025-04-08
Type : Chemical
Substance Number : 553
Ethambutol Hydrochloride, Process-II
Certificate Number : CEP 2023-224 - Rev 00
Status : Valid
Issue Date : 2023-09-07
Type : Chemical
Substance Number : 553
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
64
PharmaCompass offers a list of Ethambutol Dihydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ethambutol Dihydrochloride manufacturer or Ethambutol Dihydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ethambutol Dihydrochloride manufacturer or Ethambutol Dihydrochloride supplier.
PharmaCompass also assists you with knowing the Ethambutol Dihydrochloride API Price utilized in the formulation of products. Ethambutol Dihydrochloride API Price is not always fixed or binding as the Ethambutol Dihydrochloride Price is obtained through a variety of data sources. The Ethambutol Dihydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A E1011 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of E1011, including repackagers and relabelers. The FDA regulates E1011 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. E1011 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of E1011 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A E1011 supplier is an individual or a company that provides E1011 active pharmaceutical ingredient (API) or E1011 finished formulations upon request. The E1011 suppliers may include E1011 API manufacturers, exporters, distributors and traders.
click here to find a list of E1011 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A E1011 DMF (Drug Master File) is a document detailing the whole manufacturing process of E1011 active pharmaceutical ingredient (API) in detail. Different forms of E1011 DMFs exist exist since differing nations have different regulations, such as E1011 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A E1011 DMF submitted to regulatory agencies in the US is known as a USDMF. E1011 USDMF includes data on E1011's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The E1011 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of E1011 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The E1011 Drug Master File in Japan (E1011 JDMF) empowers E1011 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the E1011 JDMF during the approval evaluation for pharmaceutical products. At the time of E1011 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of E1011 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a E1011 Drug Master File in Korea (E1011 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of E1011. The MFDS reviews the E1011 KDMF as part of the drug registration process and uses the information provided in the E1011 KDMF to evaluate the safety and efficacy of the drug.
After submitting a E1011 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their E1011 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of E1011 suppliers with KDMF on PharmaCompass.
A E1011 CEP of the European Pharmacopoeia monograph is often referred to as a E1011 Certificate of Suitability (COS). The purpose of a E1011 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of E1011 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of E1011 to their clients by showing that a E1011 CEP has been issued for it. The manufacturer submits a E1011 CEP (COS) as part of the market authorization procedure, and it takes on the role of a E1011 CEP holder for the record. Additionally, the data presented in the E1011 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the E1011 DMF.
A E1011 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. E1011 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of E1011 suppliers with CEP (COS) on PharmaCompass.
A E1011 written confirmation (E1011 WC) is an official document issued by a regulatory agency to a E1011 manufacturer, verifying that the manufacturing facility of a E1011 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting E1011 APIs or E1011 finished pharmaceutical products to another nation, regulatory agencies frequently require a E1011 WC (written confirmation) as part of the regulatory process.
click here to find a list of E1011 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing E1011 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for E1011 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture E1011 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain E1011 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a E1011 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of E1011 suppliers with NDC on PharmaCompass.
E1011 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of E1011 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right E1011 GMP manufacturer or E1011 GMP API supplier for your needs.
A E1011 CoA (Certificate of Analysis) is a formal document that attests to E1011's compliance with E1011 specifications and serves as a tool for batch-level quality control.
E1011 CoA mostly includes findings from lab analyses of a specific batch. For each E1011 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
E1011 may be tested according to a variety of international standards, such as European Pharmacopoeia (E1011 EP), E1011 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (E1011 USP).